



DENGUE

A TOOLKIT FOR NATIONAL
DENGUE BURDEN ESTIMATION



World Health
Organization

A TOOLKIT FOR NATIONAL DENGUE BURDEN ESTIMATION

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-ncsa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. A Toolkit for national dengue burden estimation, Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>. Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout: Patrick Tissot WHO/NTD

WHO/CDS/NTD/VEM/2018.05



CONTENTS

Acknowledgements	v
Abbreviations	vi
Introduction	1
Aim	1
Measuring burden	2
Levels of disease severity of dengue infections.....	2
Why current surveillance systems may misestimate the clinical burden of dengue	4
Toolkit overview	7
Suggested dengue surveillance standards for burden estimation	10
1.1. Collating and reporting dengue surveillance data.....	10
1.2. Completeness assessment of national dengue surveillance data.....	13
1.3. Over-diagnosis analysis	15
1.4. Under-diagnosis analysis	18
1.5. Febrile cohorts	20
Febrile illness surveys	20
Measuring inapparent incidence within febrile illness cohorts.....	22
1.6. Measuring total infections using cross-sectional seroprevalence surveys	23
Burden calculation	24
2.1. Using the burden calculator	24
2.2. Comparison with global dengue burden modelling estimates	29
Further extension studies.....	30
3.1. Spatial variation in burden	30
3.2. Economic burden of dengue.....	31
3.3. Combined arboviral burden	32
3.4. Reducing uncertainty in burden estimates	33
3.5. Evaluating change in burden over time	34
References	36





ACKNOWLEDGEMENTS

This toolkit is the product of a series of meetings of the World Health Organization (WHO) Advisory Group on dengue burden estimation. The document was developed on behalf of WHO by Oliver J. Brady (London School of Hygiene & Tropical Medicine).

All members of the Advisory Group also contributed to and approved the final version of the toolkit document and are listed here (in alphabetical order): Mathieu Bangert (WHO), Gamaliel Gutierrez Castillo (Pan American Health Organization), Ng Lee Ching (National Environment Agency's Environmental Health Institute), Derek Cummings (University of Florida), Zoey Diaz (BMGF), Neil Ferguson (Imperial College London), Simon Hay (Institute for Health Metrics and Evaluation), Joaquim

Hombach (WHO), Thomas Jaenisch (University of Heidelberg), Mohamed Jamsheed (WHO), Jacqueline Lim (International Vaccine Institute), Robert Reiner Jr (Institute for Health Metrics and Evaluation), Thomas Scott (University of California, Davis), Donald Shepard (Brandeis University), Jeff Stanaway (Institute for Health Metrics and Evaluation) and Raman Velayudhan (WHO).

Input was also provided by various individuals from the health ministries and WHO offices in Brazil, Cambodia, Maldives, Mexico and Sri Lanka as well as by Maïna L'Azou (Sanofi Pasteur).

Funding for the production of this toolkit and its development was gratefully received from the Bill & Melinda Gates Foundation (BMGF).



ABBREVIATIONS

DENV	dengue virus	ELISA	enzyme-linked immunosorbent assay
PPV	positive predictive value	HI	haemagglutination inhibition
UFI	unidentified febrile illness	PRNT	plaque reduction neutralization test
DHS	Demographic and Health Surveys	FOI	force of infection
IgM/G	immunoglobulin M or G	WHO	World Health Organization
PCR	polymerase chain reaction		

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25481